Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547163 | 1.00 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL3547159 | 1.00 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL3544439 | 0.80 | — | — | |
| SCHEMBL5415881 | 0.80 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5420828 | 0.80 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5012689 | 0.79 | ADORA2A (0.54) | ADORA2AADORA1ADORA2B | |
| SCHEMBL5013365 | 0.78 | ADORA2A (0.61) | ADORA2A | |
| SCHEMBL9325950 | 0.78 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL3546137 | 0.76 | — | — | |
| SCHEMBL5012692 | 0.76 | ADORA2A (0.57) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834014-B2 | Parkinson's disease; [2-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-octahydro-pyrido[1,2-a]pyrazin-7-yl]-methanol; | BIOGEN IDEC MA INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1633756-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | disclosed |
| EP-1633756-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004092173-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.